AG真人官方

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

New Bay Area Building Marks Significant Progress as Part of $32 Billion U.S. Investment Projected to Create $43 Billion in Economic Value

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company鈥檚 Foster City headquarters. This milestone marks continued momentum in Gilead鈥檚 multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities. It is part of Gilead鈥檚 planned $32 billion investment in U.S. innovation through 2030. This investment is projected to generate more than $43 billion in economic value nationwide, strengthening America鈥檚 biopharmaceutical leadership while fueling high-quality jobs, research, and domestic manufacturing.

Gilead Sciences breaks ground on new manufacturing and technical development site in Bay Area.

鈥淭his new facility is part of our vision for delivering next generation therapies and a cornerstone of Gilead鈥檚 $32 billion investment commitment in the United States,鈥� said Daniel O鈥橠ay, Chairman and Chief Executive Officer of Gilead Sciences. 鈥淲e have multiple construction projects underway, all of which will generate thousands of American jobs and help to drive U.S. leadership in global biopharma innovation.鈥�

The five-story, 180,000 square foot facility will serve as a hub for innovation and collaboration across technical development and manufacturing teams. Designed with flexible pilot lab space and advanced digital infrastructure, the NTDC will accelerate technology transfer and support the advancement of next-generation biologics across Gilead鈥檚 pipeline. It will feature digitally enabled systems, autonomous robotics, and real-time digital monitoring, making it one of the most AI-enabled centers in the biopharma industry.

The new facility will strengthen Gilead鈥檚 biologics capacity and capabilities, a central pillar of the company鈥檚 growth strategy. This investment builds on Gilead鈥檚 broader U.S. efforts to expand research and manufacturing, create more than 3,000 direct and indirect high-quality jobs, and advance equitable access to healthcare nationwide.

鈥淐alifornia is proud to be home to Gilead Sciences and its ongoing investment in innovation and jobs right here in Foster City,鈥� said California Lieutenant Governor Eleni Kounalakis. 鈥淭his new Technical Development Center is more than a milestone for Gilead; it鈥檚 a win for all who will benefit from its breakthroughs. It demonstrates that when we invest in domestic biomanufacturing, we strengthen supply chains, create thousands of good-paying jobs, and keep America at the forefront of life-saving innovation.鈥�

This groundbreaking is part of a broader expansion at Gilead鈥檚 Foster City headquarters. In addition to the NTDC, the company is currently developing two other state-of-the-art facilities: a new research building designed to accelerate scientific discovery, already under construction, and a biologics manufacturing facility that will expand domestic production capacity. These current investments further build on Gilead鈥檚 strong history of U.S. investment, with more than $15 billion over the last decade, and reinforce the company鈥檚 role as a major contributor to the U.S. biopharmaceutical industry and a vital partner in driving scientific innovation and solutions for patients. Together, these investments form an integrated innovation ecosystem designed to accelerate discovery, streamline manufacturing, and reinforce Gilead鈥檚 role as a U.S.-based biopharma leader in improving human health globally.

Today鈥檚 event features remarks from Gilead leadership including Daniel O鈥橠ay, CEO, Stacey Ma, Executive Vice President, Pharmaceutical Development and Manufacturing, and Joydeep Ganguly, Senior Vice President, Corporate Operations. Distinguished guests include:

• California Lieutenant Governor Eleni Kounalakis
• Rosanne Foust and Larisa Ocanada, San Mateo County Economic Development Association
• Tim Scott, CEO of Biocom
• Supervisor Noelia Corzo, San Mateo County Board of Supervisors

For more information on Gilead鈥檚 U.S. investments, visit: .

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

For more information about Gilead, please visit the company鈥檚 website at , follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

View source version on businesswire.com:

Jessica Smith, Media

[email protected]



Jacquie Ross, Investors

[email protected]

Source: Gilead Sciences, Inc.